Compare Natera Inc. Common Stock (NTRA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Tripadvisor Inc Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Tripadvisor Inc Common Stock trades at $8.93 (market cap $1.02B). The key difference: Natera Inc. Common Stock is far larger — about 55.9× Tripadvisor Inc Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Tripadvisor Inc Common Stock for 58 Days on average.
| NTRA | TRIP | |
|---|---|---|
Market Cap | $57.03B | $1.02B |
Volume | 1,131,157 | 1,973,736 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $16.72 |
52-Week Low | $179.42 | $8.04 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $56.18B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TripAdvisor (TRIP) trades at $8.93, up 2.41% today but near its 52-week low of $8.27. The stock shows neutral technical signals with bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 2.11%, though recent quarters show earnings misses. The P/E ratio of 218.5 reflects high valuation relative to earnings, while P/S of 0.57 suggests reasonable sales valuation. Analyst sentiment is mixed with 62.5% hold ratings.
The outlook remains cautious due to competitive pressures from AI travel tools and uneven demand. Upside exists if Viator performance improves and TheFork sale completes, but risks include persistent earnings volatility and market share erosion. The consensus price target of $13.58 offers 52% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
